Neurofeedback Emerges as Rehabilitation Strategy for Parkinson's

A narrative review published in Frontiers positions neurofeedback as an emerging rehabilitation strategy for Parkinson's disease, surveying a training approach in which patients learn to self-regulate neural activity captured by EEG and related recording methods rather than relying on pharmacology alone.

The review's core claim is procedural, not diagnostic. Neurofeedback in this context means real-time display of a patient's own brain signals — typically scalp EEG — so the patient can practice modulating those rhythms over repeated sessions. The authors frame it as a candidate adjunct to standard dopaminergic treatment and physical rehabilitation, not a replacement for either.

What does the review actually cover?

As a narrative review rather than a randomized controlled trial or meta-analysis, the paper synthesizes existing literature on neurofeedback applied to Parkinson's motor and non-motor symptoms. This format matters for readers in clinical neurophysiology: it maps the field and identifies gaps, but it does not generate new patient-level outcome data.

Key elements the review addresses:

• Rationale: Parkinson's disease involves altered oscillatory brain activity, and neurofeedback targets voluntary modulation of these aberrant rhythms.
• Modality: the training paradigm rests on EEG-derived signal feedback, placing it within reach of conventional neurophysiology labs already equipped for scalp recording.
• Population: patients undergoing rehabilitation for Parkinson's symptoms, where drug-related fluctuations and motor complications motivate non-pharmacological adjuncts.
• Evidence status: the authors characterize the strategy as emerging, signaling that the literature remains limited relative to established interventions.

How should reading rooms and rehab labs read this?

For clinical neurophysiologists, the practical relevance lies in the recording requirements. A neurofeedback protocol demands stable scalp EEG acquisition during active task performance, real-time signal processing, and feedback latency tight enough that patients can associate their mental strategy with the displayed signal. Labs already running quantitative EEG or long-term monitoring have the acquisition infrastructure; the additional components are the real-time feedback loop and a structured training curriculum.

For movement-disorder clinicians, the review's framing suggests a referral-relevant question: which Parkinson's patients might benefit from adjunctive, EEG-based self-regulation training alongside medication and physiotherapy? The review's own cautious language — "emerging" rather than "established" — should temper expectations until controlled trials define responder profiles, optimal session counts, and durability of any benefit.

Investigational, not FDA-cleared

The work surveyed in the review is investigational. No neurofeedback protocol for Parkinson's rehabilitation described here carries an established regulatory clearance as a disease-modifying or standard-of-care therapy, and the review does not claim otherwise. Neurofeedback equipment itself exists in both research-grade and clinically marketed configurations, but the application to Parkinson's rehabilitation remains under study.

This distinction matters for how findings are communicated to patients. Clinicians quoting this review should describe neurofeedback as a research-supported training strategy under evaluation — with EEG as the named recording method — rather than as a validated treatment for Parkinson's motor symptoms.

Where the field goes next

The review points toward the standard next steps for any rehabilitation modality seeking clinical adoption: controlled trials with defined outcomes, standardized feedback protocols, and comparison against active control conditions. As the authors indicate, neurofeedback for Parkinson's disease has moved from concept to preliminary human studies; whether it earns a place in routine rehabilitation now depends on the trial data those studies generate.